Cutaneous T-cell lymphomas arise in the skin and are classified by their clinical presentation and cell surface markers. Mycosis fungoides and the Sezary syndrome are the most frequently encountered, followed by the CD30+ lymphoproliferative disorders. The therapy for cutaneous T cell lymphomas (CTCL) depends on the stage of the patient and skin-directed therapy is used for early stages. New targeted therapies for CTCL have become available in the past two decades; however, CTCL remains largely incurable in advanced stages.